These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 38850023)

  • 41. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.
    Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A
    J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models.
    Ellinwood NM; Vite CH; Haskins ME
    J Gene Med; 2004 May; 6(5):481-506. PubMed ID: 15133760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene therapy for lysosomal storage disorders.
    Gritti A
    Expert Opin Biol Ther; 2011 Sep; 11(9):1153-67. PubMed ID: 21548845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems.
    Beraza-Millor M; Rodríguez-Castejón J; Del Pozo-Rodríguez A; Rodríguez-Gascón A; Solinís MÁ
    BioDrugs; 2024 Sep; 38(5):657-680. PubMed ID: 39177875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
    Meena NK; Raben N
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inherited disorders of lysosomal membrane transporters.
    Huizing M; Gahl WA
    Biochim Biophys Acta Biomembr; 2020 Dec; 1862(12):183336. PubMed ID: 32389669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SNX8 enables lysosome reformation and reverses lysosomal storage disorder.
    Li X; Xiang C; Zhu S; Guo J; Liu C; Wang A; Cao J; Lu Y; Neculai D; Xu P; Feng XH
    Nat Commun; 2024 Mar; 15(1):2553. PubMed ID: 38519472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Journey towards Understanding the Molecular Pathology and Developing Therapies for Lysosomal Storage Disorders.
    Tikkanen R
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy for lysosomal storage diseases and peroxisomal diseases.
    Ohashi T
    J Hum Genet; 2019 Feb; 64(2):139-143. PubMed ID: 30498239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular Trojan Horses for treating lysosomal storage diseases.
    Leal AF; Inci OK; Seyrantepe V; Rintz E; Celik B; Ago Y; León D; Suarez DA; Alméciga-Díaz CJ; Tomatsu S
    Mol Genet Metab; 2023 Nov; 140(3):107648. PubMed ID: 37598508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lysosomal storage diseases.
    Platt FM; d'Azzo A; Davidson BL; Neufeld EF; Tifft CJ
    Nat Rev Dis Primers; 2018 Oct; 4(1):27. PubMed ID: 30275469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases.
    Seranova E; Connolly KJ; Zatyka M; Rosenstock TR; Barrett T; Tuxworth RI; Sarkar S
    Essays Biochem; 2017 Dec; 61(6):733-749. PubMed ID: 29233882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
    Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
    Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases.
    Heller G; Bradbury AM; Sands MS; Bongarzone ER
    Mol Ther; 2023 Jan; 31(1):7-23. PubMed ID: 36196048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders.
    Wang A; Chen C; Mei C; Liu S; Xiang C; Fang W; Zhang F; Xu Y; Chen S; Zhang Q; Bai X; Lin A; Neculai D; Xia B; Ye C; Zou J; Liang T; Feng XH; Li X; Shen C; Xu P
    Nat Cell Biol; 2024 Feb; 26(2):219-234. PubMed ID: 38253667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Astrocytes and lysosomal storage diseases.
    Rama Rao KV; Kielian T
    Neuroscience; 2016 May; 323():195-206. PubMed ID: 26037807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.